Newsroom
Zhifei and GSK reached strategic cooperation, adding a new blockbuster...
Zhifei and GSK reached strategic cooperation, adding a new blockbuster product
2023-10-12
On October 8, 2023, Chongqing Zhifei Biological Products Co., Ltd. (hereinafter referred to as "Zhifei") and GlaxoSmithKline (GSK Biologica...
see details 》
Zhifei Longcom Recombinant COVID-19 Vaccine Receives Marketing Approva...
Zhifei Longcom Recombinant COVID-19 Vaccine Receives Marketing Approval in Kenya
2022-12-23
On December 22, the Company's Recombinant COVID-19 Vaccine (CHO Cell) was approved for marketing by the Pharmacy and Poisons Board (PPB) of...
Zhifei Longcom Passes EU QP Audit, An Acceleration in Zhifei’s Intern...
Zhifei Longcom Passes EU QP Audit, An Acceleration in Zhifei’s International Strategic Layout
2022-11-09
On November 8, 2022, the Recombinant COVID-19 Vaccine (CHO Cell) and the Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell) of An...
Zhifei and GSK reached strategic cooperation, adding a new blockbuster product2023-10-12
Zhifei - Beijing R&D center expands to build innovative product incubation center2023-03-28
Based on the original technology platform of the R&D center in Beijing, Zhifei once again expands its R&D layout and builds an innovative p...
MSD and Zhifei Renew Collaboration on Vaccines2023-03-02
On January 21, 2023, through friendly negotiations between the two parties, Zhifei and MSD renewed the agreement on Supply, Distribution and...
Zhifei Longcom Recombinant COVID-19 Vaccine Receives Conditional Marketing Approval in Belarus2023-01-04
On January 3, local time, Zhifei longcom Recombinant COVID-19 Vaccine (CHO Cell) was approved for Conditional Marketing Approval by the Min...
Zhifei Longcom Recombinant COVID-19 Vaccine Receives Marketing Approval in Kenya2022-12-23